Advertisement
Advertisement
PACB
Pacific Biosciences of California, Inc.
1.14
USDSponsored
-0.01
-0.87%
Aug 11, 15:48 UTC -4
Closed
Pre-Market
1.19
+0.05
+3.95%
PACB Earnings Reports
Positive Surprise Ratio
PACB beat 21 of 42 last estimates.
50%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$41.40M
/-$0.13
Implied change from Q2 26 (Revenue/ EPS)
+6.14%
/-7.14%
Implied change from Q3 25 (Revenue/ EPS)
+7.70%
/--
Pacific Biosciences of California, Inc. earnings per share and revenue
On Aug 05, 2026, PACB reported earnings of -0.14 USD per share (EPS) for Q2 26, missing the estimate of -0.12 USD, resulting in a -7.94% surprise. Revenue reached 39.01 million, compared to an expected 40.87 million, with a -4.55% difference. The market reacted with a -10.38% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 41.40 million USD, implying an decrease of -7.14% EPS, and increase of 6.14% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Tactile Systems Technology, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.14
Actual
$0.34
Surprise
+131.45%
Mesa Laboratories Inc
Report Date
Aug 10, 2026 For Q1 27
Estimate
$0.03
Actual
$2.61
Surprise
+8,429.41%
Mobia Medical, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.65
Actual
-$0.88
Surprise
-33.41%
908 Devices Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.17
Actual
-$0.11
Surprise
+36.56%
Treace Medical Concepts, Inc. Common Stock
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.30
Actual
-$0.24
Surprise
+21.05%
Neuronetics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+60.00%
Stereotaxis, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+1.96%
Xtant Medical Holdings, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.07
Surprise
-243.14%
Spectral AI, Inc. Class A Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.13
Surprise
+5.59%
DarioHealth Corp. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.23
Actual
-$0.56
Surprise
+54.01%
FAQ
What were Pacific Biosciences of California, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Pacific Biosciences of California, Inc. reported EPS of -$0.14, missing estimates by -7.94%, and revenue of $39.01M, -4.55% below expectations.
How did the market react to Pacific Biosciences of California, Inc.'s Q2 2026 earnings?
The stock price moved down -10.38%, changed from $1.30 before the earnings release to $1.17 the day after.
When is Pacific Biosciences of California, Inc. expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Pacific Biosciences of California, Inc.'s next earnings report?
Based on 10
analysts, Pacific Biosciences of California, Inc. is expected to report EPS of -$0.13 and revenue of $41.40M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement